Buprenorphine pharmacology

Similar documents
Dr Alistair Dunn. General Practitioner Whangarei

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Steven Prakken MD Director Medical Pain Service Duke Pain Medicine

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM

USE OF BUPRENORPHINE FOR CHRONIC PAIN

OST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

Methadone Maintenance

GOALS AND OBJECTIVES

Opiate Dependency bka Opioid Addiction

Buprenorphine as a Treatment Option for Opioid Use Disorder

Medication-Assisted Treatment (MAT) Overview

Medication Assisted Treatment

Latest Press Release. How much for 30 mg adderall

Opioids. Sergio Hernandez, MD

Opioid Conversion Guidelines

Building capacity for a CHC response to Ontario's Opioid Crisis

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Talking with your doctor

Morphine equivalent calculator suboxone

Opioids Research to Practice

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE

Buprenorphine Access in California

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018

MEDICATION ASSISTED TREATMENT

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS

Medication Assisted Treatment. Michael Palladini, RPh MBA CAC

Opioids Research to Practice

Opioids- Indica-ons, Equivalence, Dependence and Withdrawal Methadone Maintenance (OST) Paul Glue

Opioids Research to Practice

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services

A prisoners guide to buprenorphine

WR Fentanyl Symposium. Opioids, Overdose, and Fentanyls

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018

What do they have in common?

The Rising Tide of Prescription Opioid Use Disorders and Current Treatment Options

Buprenorphine addiction

Prescription Opioid Addiction

Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018

Module II Opioids 101 Opiate Opioid

Module Two: Pharmacotherapies for Opioid Substitution Treatment

How soon does tramadol withdrawal start

Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists

Vivitrol Vs. Suboxone

Medication Assisted Treatment. Nicole Gastala, MD

Medication-assisted opioid addiction treatments: OB/GYN

Opioid dependence and buprenorphine treatment

MEDICALLY ASSISTED TREATMENT IN PROBLEMATIC OPIOID Punta Cana 2018

Opioid Use Disorders &Medication Treatment

Opioid Dependence and Buprenorphine Management

Overview of Opioid Use Disorder

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.

Opioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.

Charles P. O Brien, MD, PhD University of Pennsylvania No financial conflicts, patents, speakers bureaus

Opioid Use in Youth. Amy Yule M.D. March 2,

Treatment Alternatives for Substance Use Disorders

Fentanyls and Naloxone. Opioids, Overdose, and Naloxone

Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations

15 mg morphine 10 mg hydrocodone

5/29/2015. Responding to the Opioid Crisis. Responding to the Opioid Crisis. Objectives

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

PAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)

Opioids Research to Practice

May 25, To examine the frequency of buprenorphinerelated discussions on the web forum, PREDOSE extract data on the number of posts per year

12/14/2018. Disclosures. Buprenorphine. Drug-Receptor Interactions. Affinity

Safe Practices and Action Items

National Opioid Treatment Guideline Dr. Ronald Lim

4/5/2018 MEDICATION ASSISTED TREATMENT FOR OPIOID USE DISORDERS OBJECTIVES DEFINITION OF ADDICTION APRIL 11, 2018 RITU BHATNAGAR, M.D., M.P.H.

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

Long term treatment for opioid dependence Antagonist therapy

2004-L SEPTEMBER

VOLUME C. Pharmacological Treatment for Drug Use Disorders Drug Treatment for Special Populations

Identification and Treatment of Opioid Use Disorders in Primary Care Settings

Opioid Replacement Therapy

Michael O Neil, Pharm.D. Professor and Vice-Chair, Department of Pharmacy Practice Drug Diversion, Substance Abuse, and Pain Management Consultant

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17

Acute pain management in opioid tolerant patients. Muhammad Laklouk

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

Analgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015

Opioids Research to Practice

Opiates & Opioids Opioids

Karen F Marlowe, Pharm D, BCPS Certified Pain Educator Auburn University Harrison School of Pharmacy University of South Alabama School of Medicine

New Zealand Clinical Guidelines for the Use of Buprenorphine (with or without Naloxone) in the Treatment of Opioid Dependence

Disclosure Statement. Learning Objectives. American Psychiatric Nurses Association. Christian J. Teter, PharmD, BCPP 1 BUPRENORPHINE UPDATE

John Murphy DO, MS Lynx Healthcare

6/6/2018. Nalbuphine: Analgesic with a Niche. Mellar P Davis MD FCCP FAAHPM. Summary of Advantages. Summary of Advantages

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Medication-Assisted Treatment (MAT) for Opioid Use Disorders

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

Opioid Treatment in North Carolina SEPTEMBER 13, 2016

OP01 [Mar96] With regards to pethidine s physical properties: A. It has an octanol coefficient of 10 B. It has a pka of 8.4

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA

Opioid Conversions Mixture of Science and Art

PAIN RELIEF AFTER SURGERY

Transcription:

Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1

Opioids full, partial, antagonist Full Agonists - bind completely and strongly to receptors creating maximum effect. These include oxycodone, heroin, fentanyl Partial Agonists are similar to full agonists at low doses, however cause less receptor activation, and at high doses analgesic effects plateau. These include buprenorphine and tramadol Antagonists Bind and block receptors and therefore biological response. This includes naloxone and naltrexone Page 2

Opiate effect Opioids full, partial, antagonist 60 50 Morphine, heroin, oxycodone, methadone, codeine 40 30 20 Buprenorphine 10 0 Dose Naltrexone, naloxone

Buprenorphine Has high affinity for the opioid receptor Competes with other opioids for the receptors Binds to receptors in preference to full opioid agonists Has limited opioid effect, stopping withdrawal but not causing euphoria At 24-72 hours, begins to dissipate from receptors Page 4

Buprenorphine - onset of action, duration Sublingual film Onset is between 30 to 60 minutes Peak effect occurs between 1 to 4 hours Effect on controlling craving can be from 24 to 72 hours as buprenorphine dissipates from the receptors Page 5

Side effects of buprenorphine Most dissipate after medication is taken for awhile Uncommon Sometimes: Agitation / feeling wired / buzzing (lessened sedative effect) Flu like symptoms / body aches / headaches Dizziness QT prolongation Constipation Sweating Sleep problems Nb. Cases of hypersensitivity to buprenorphine have been reported (rare) Page 6

Formulations opioid maintenance tx Must have permit for OST Subutex Nb no takeaways Suboxone Nb TA s allowed Page 7

Formulations opioid maintenance tx Buprenorphine is being increasingly used > Safety profile Individuals should wait until withdrawal symptoms occur before starting Buprenorphine as it can precipitate withdrawal for people who are currently dependent on another opiate Page 8

Naloxone in Suboxone Naloxone in Suboxone is intended to reduce its abuse liability (c.f. Subutex): Very low bioavailability: <2% absorbed Meant to block the effect of buprenorphine if it is injected Only precipitates withdrawal if injected and opioid on board Page 9

Precipitated withdrawal Precipitated withdrawal is a rapid intense onset withdrawal symptoms Hence start dose is 4mg Or can do test dose of 2mg - within 1 hr will know Occurs when Buprenorphine is given to an individual who is physically dependent on full agonist opioids: The partial agonist kicks off the already existing opioid agonist, causing a sudden loss of opioid receptor activation Page 10

Precipitated withdrawal - mx Administer 2-4mg buprenorphine doses hourly until symptoms settle Page 11

Methadone to buprenorphine transfer Methadone 30-40mg: can transfer to buprenorphine in community (Higher methadone doses need inpatient admission) Wait 36-48 hours after last dose of methadone (the longer the better) to avoid precipitated withdrawal Start buprenorphine at 4mg BD then can increase dose quickly Daily review Page 12

Formulations - pain Temgesic Injections IM or slow IV (eg. 300-600 mcg qid or tds) Sublingual tablets (eg. 200 mcg; 1-2 tab qid or tds ) Norspan Patches 5mcg/hr, 10 mcg/hr, 20 mcg/hr Maximum 2 concurrent patches at a time Page 13

Buprenorphine - overlap dependence & pain Suboxone and Subutex: off label for pain management Nb. Pain specialist review needed - still need an OST permit Analgesic effects gained through action at Mu receptors throughout the central nervous system Has a ceiling on analgesic effect because it is a partial agonist Page 14

Mx of acute pain while on Suboxone Page 15

Questions and discussion Page 16